Purpose of this Study
We are doing this study to identify patients who have gene changes or mutations in their tumor(s) and might be eligible for treatment using a combination of targeted therapy options. This study is called ComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice).
Who Can Participate?
Eligibility
Adults ages 18+ who:<ul>
<li>Have measurable disease</li>
<li>Are deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider</li>
<li>Have progressed after one course of standard therapy or are not able to be treated with standard therapy</li></ul>
For more information about this study, please contact the study team at <a href="mailto: nick.jeffries@duke.edu">nick.jeffries@duke.edu.</a>
<li>Have measurable disease</li>
<li>Are deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider</li>
<li>Have progressed after one course of standard therapy or are not able to be treated with standard therapy</li></ul>
For more information about this study, please contact the study team at <a href="mailto: nick.jeffries@duke.edu">nick.jeffries@duke.edu.</a>
What is Involved?
This study is a registration study to see who might be eligible for upcoming ComboMATCH drug trials.
If you choose to join, you will have a sample of your tumor tested by a ComboMATCH-designated laboratory. If the tests show that you may be able to participate in the ComboMATCH program, the results and some of your health information will be sent by your doctor or the ComboMATCH-designated laboratory to Precision Medicine Analysis Coordination Center (PMACC) to be used to determine if you are eligible for a ComboMATCH treatment trial.
You can read more about ComboMATCH on the National Cancer Institute website: <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/combomatch">https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/combomatch</a>
If you choose to join, you will have a sample of your tumor tested by a ComboMATCH-designated laboratory. If the tests show that you may be able to participate in the ComboMATCH program, the results and some of your health information will be sent by your doctor or the ComboMATCH-designated laboratory to Precision Medicine Analysis Coordination Center (PMACC) to be used to determine if you are eligible for a ComboMATCH treatment trial.
You can read more about ComboMATCH on the National Cancer Institute website: <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/combomatch">https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/combomatch</a>
Study Details
Full Title
EAY191 Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Principal Investigator
John
Strickler
Protocol Number
PRO00113715
NCT ID
NCT05564377
Phase
0
Enrollment Status
Open to Enrollment